OncoMatch/Clinical Trials/NCT06390956
Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL)
Is NCT06390956 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Pirtobrutinib and Rituximab for marginal zone lymphoma.
Treatment: Pirtobrutinib · Rituximab — The purpose of this clinical trial is to learn if the drugs Pirtobrutinib and Rituximab are effective for the treatment of newly diagnosed marginal zone lymphoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: antibiotic therapy — for H. pylori, C. psittaci, and B. burgdorferi
Prior antibiotic therapy for H. pylori, C. psittaci, and B. burgdorferi
Must have received: antiviral therapy — for HCV
Prior antiviral therapy for HCV
Lab requirements
Blood counts
ANC ≥ 750 cells/mm3 (≥ 0.75 x 10^9/L) independent of G-CSF support (≥500 if bone marrow involvement or splenomegaly); Platelet count ≥ 50,000/mm3 (≥30,000 if bone marrow involvement); Hemoglobin ≥ 8 g/dL (≥7 g/dL if bone marrow involvement or splenomegaly)
Kidney function
Estimated creatinine clearance ≥ 30 mL/min by Cockcroft-Gault formula
Liver function
Total Bilirubin ≤ 1.5x ULN (≤3x ULN if liver involvement); AST(SGOT)/ALT(SGPT) ≤ 3 × ULN (≤5x ULN if liver metastases)
Cardiac function
QTcF ≤ 470 ms; LVEF ≥ 40% within 12 months prior to first dose
Adequate organ function as defined as: Hematologic: ANC ≥ 750 cells/mm3...; Platelet count ≥ 50,000/mm3...; Hemoglobin ≥ 8 g/dL...; Hepatic: Total Bilirubin ≤ 1.5x ULN...; AST(SGOT)/ALT(SGPT) ≤ 3 × ULN...; Renal: Estimated creatinine clearance ≥ 30 mL/min by Cockcroft-Gault formula; aPPT or PT or INR ≤ 1.5 X ULN; Cardiac: QTcF > 470 ms excluded, LVEF < 40% excluded
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Washington University · St Louis, Missouri
- Huntsman Cancer Institute at University of Utah · Salt Lake City, Utah
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify